Jane Street’s Jyong Biotech MENS Stock Holding History

Jane Street’s Portfolio MENS Stock Details MENS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-69,560	Closed	-$275K	–	13494
2025 Q4	$275K	Buy	+69,560	New	+$2.46M	﹤0.01%	9039

Other funds holding MENS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jane Street's MENS Position: Q1 2026 in Review

Jane Street sold out of Jyong Biotech (MENS) in Q1 2026, closing a stake of 69,560 shares — an estimated $275K sold.

Jane Street first reported a position in MENS in Q4 2025 and held it in 1 quarter. The position peaked at $275K in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

Jane Street reported no remaining Jyong Biotech position as of Q1 2026 after selling out during the quarter.
Jane Street sold 69,560 Jyong Biotech shares in Q1 2026, an estimated $275K.
Jane Street first reported a position in Jyong Biotech in Q4 2025 and held it in 1 quarter.
Jane Street's Jyong Biotech position peaked at $275K in Q4 2025.
17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.